- Home
- EXAS vs KT Comparison
EXAS vs KT Comparison
Compare EXAS & KT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- KT
- Stock Information
- Founded
- EXAS 1995
- KT 1981
- Country
- EXAS United States
- KT South Korea
- Employees
- EXAS N/A
- KT N/A
- Industry
- EXAS Medical Specialities
- KT Telecommunications Equipment
- Sector
- EXAS Health Care
- KT Telecommunications
- Exchange
- EXAS Nasdaq
- KT Nasdaq
- Market Cap
- EXAS 11.0B
- KT 8.9B
- IPO Year
- EXAS N/A
- KT 1999
- Fundamental
- Price
- EXAS $100.87
- KT $17.61
- Analyst Decision
- EXAS Strong Buy
- KT
- Analyst Count
- EXAS 18
- KT 0
- Target Price
- EXAS $72.44
- KT N/A
- AVG Volume (30 Days)
- EXAS 7.2M
- KT 1.3M
- Earning Date
- EXAS 11-03-2025
- KT 11-11-2025
- Dividend Yield
- EXAS N/A
- KT 3.64%
- EPS Growth
- EXAS N/A
- KT N/A
- EPS
- EXAS N/A
- KT 2.83
- Revenue
- EXAS $3,082,033,000.00
- KT $19,913,724,353.00
- Revenue This Year
- EXAS $16.68
- KT N/A
- Revenue Next Year
- EXAS $12.36
- KT N/A
- P/E Ratio
- EXAS N/A
- KT $11.85
- Revenue Growth
- EXAS 14.47
- KT 5.75
- 52 Week Low
- EXAS $38.81
- KT $15.01
- 52 Week High
- EXAS $101.87
- KT $21.61
- Technical
- Relative Strength Index (RSI)
- EXAS 91.11
- KT 33.05
- Support Level
- EXAS $66.00
- KT $18.00
- Resistance Level
- EXAS $69.08
- KT $18.21
- Average True Range (ATR)
- EXAS 3.80
- KT 0.32
- MACD
- EXAS 2.49
- KT -0.03
- Stochastic Oscillator
- EXAS 97.30
- KT 7.39
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About KT KT Corporation
KT is South Korea's largest fixed-line telecom operator, with around 11.5 million fixed-line broadband customers and 9.4 million IPTV customers, and is the second-largest wireless operator with 26 million subscribers. Additionally, it has a number of nontelecom businesses, including real estate, payment processing, artificial intelligence, and IDC/cloud services, many of which are the focus of its growth strategy. The company was formed from the previously government-owned, monopoly telecom business and was listed in 1998. After selling its mobile business in 1994 (forming its mobile competitor, SK Telecom) KT created its own mobile operator in 1997.